Fig. S1. Mean satisfaction with currently prescribed systemic medication. (A) When satisfaction was assessed by choice between 5 categories from ‘very dissatisfied’ to ‘very satisfied’, participants treated with ustekinumab stated significantly higher satisfaction than patients with any other systemic treatment except acitretin. (B) Comparison of Treatment Satisfaction Questionnaire for Medication (TSQM) scores showed significantly higher satisfaction with ustekinumab than with infliximab, etanercept, fumaric acid esters, methotrexate, and combination therapies. Participants receiving adalimumab and acitretin had significantly higher TSQM scores than participants on methotrexate. Moreover, adalimumab, acitretin and fumaric acids were rated higher than combination therapies. (C) Subgroup analysis comparing satisfaction of participants with and without psoriatic arthritis on a 5-point scale. None of the participants treated with acitretin or fumaric acid esters suffered from arthritis. (D) TSQM scores for systemic medications reported by participants with and without arthritis. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Bars: Means with standard deviations.